Education
Oral Abstract Schedule
Thursday, October 12, 2023
Resident Oral Abstract Schedule
Sponsored by:
| Day/Time | Presenter | Abstract Title |
|---|---|---|
| Thursday 2:15 pm | Rachel McMahon | SAFETY EVALUATION OF VERDINEXOR IN COMBINATION WITH LOMUSTINE IN DOGS WITH RELAPSED MULTICENTRIC LYMPHOMA |
| Thursday 2:30 pm | Alejandra Tellez-Silva | INTERIM ANALYSIS OF A NOVEL CHEMOTHERAPY PROTOCOL THOP (TEMOZOLOMIDE, DOXORUBICIN, VINCRISTINE, PREDNISONE) FOR THE TREATMENT OF NAÏVE B-CELL LMPHOMA IN DOGS |
| Thursday 2:45 pm | Nicholas Lai | COMPARISON OF OUTCOMES IN FELINE INTERMEDIATE TO HIGH GRADE LYMPHOMA TREATED WITH MITOXANTRONE INSTEAD OF DOXORUBICIN IN MULTIAGENT CHEMOTHERAPY PROTOCOLS |
| Thursday 3:30 pm | Julia Colosi | OUTCOMES OF DOGS TREATED WITH SEQUENTIAL HALF BODY RADIOTHERAPY AND A SHORT CHOP CHEMOTHERAPY |
| Thursday 3:45 pm | Han-Yun Cheng | SURGERY AND HYPOFRACTIONATED RADIOTHERAPY FOR FELINE INJECTION SITE SARCOMA |
| Thursday 4:00 pm | Katherine Olson | LYMPHOCYTE-MONOCYTE RATIO TO PREDICT DISEASE STATUS AND OUTCOME IN DOGS WITH OSTEOSARCOMA |
| Thursday 4:15 pm | Julia Medland | CANINE OSTEOSARCOMAS SHOW EXTENSIVE HETEROGENEITY AT THE SIGNEL CELL LEVEL |
| Thursday 4:30 pm | Patrisha Paulos | THE USE OF DOXORUBICIN AND PROPRANOLOL FOR CANINE SPLENIC HEMANGIOSARCOMA: A RETROSPECTIVE STUDY OF 31 DOGS |
| Thursday 4:45 pm | Amanda Seelman | DISCOVERY OF DRUGGABLE PATHWAYS MEDIATED BY PAC-1 AND PALLADIA FOR TREATING CANINE METASTATIC INSULINOMA |
Friday, October 13, 2023 – Saturday, October 14, 2023
General Oral Abstract Schedule
Sponsored by:
| Day/Time | PRESENTER | ABSTRACT TITLE |
|---|---|---|
| Friday 1:30 pm | Shirley Chu | WHOLE EXOME SEQUENCING OF FELINE ORAL SQUAMOUS CELL CARCINOMA |
| Friday 1:45 pm | Haruka Inazumi | EFFICACY AND ADVERSE EVENTS FOLLOWING FIRST L-ASPARAGINASE ADMINISTRATION AS A FIRST-LINE TREATMENT FOR FELINE LARGE-CELL GASTROINTESTINAL LYMPHOMA |
| Friday 2:00 pm | Yohichi Fukuyama | MAGNETIC RESONANCE IMAGING SCORING SYSTEM FOR PROGNOSTIC PREDICTION IN PRESUMED CANINE INTRACRANIAL GLIOMAS TREATED WITH RADIATION THERAPY |
| Friday 2:15 pm | Matthew Berry | THERAPEUTIC DUALITY USING THE PROCASPASE-3 ACTIVATOR PAC-1 FOR SENSITIZING SOLID TUMORS TO RADIOTHERAPY |
| Saturday 9:30 am | Ruhcha Sutavani | A CANINE ANTI-CD20 MONOCLONAL ANTIBODY FOR THE TREATMENT OF CANINE B-CELL LYMPHOMA |
| Saturday 9:45 am | Andrew Callegari | INCREASED SURVIVAL AND REMISSION RATES IN PROSPECTIVE STUDY OF RELAPSED B-CELL LYMPHOMA PATIENTS TREATED BY ONCOLOGISTS USING IMPRIMED'S AI PREDICTIONS |
| Saturday 10:00 am | Sunetra Das | MOLECULAR CHARACTERIZATION OF CANINE FOLLICULAR AND MEDULLARY THYROID CARCINOMAS |
| Saturday 10:30 am | Noe Reyes | RANDOMIZED CLINICAL TRIAL EVALUATING ADOPTIVE T CELL THERAPY AS TREATMENT FOR CANINE OSTEOSARCOMA |
| Saturday 10:45 am | Daniel Gustafson | RESPONSE OF A CANINE OSTEOSARCOMA CELL LINE PANEL TO TARGETED AGENTS: AN UNBIASED SCREEN TO IDENTIFY AND VALIDATE POTENTIAL GENOMIC BIOMARKERS |
| Saturday 11:00 am | Savannah Simon | IN DOGS WITH SINONASAL CANCER, A LACK OF CYTOLOGICALLY DETECTABLE REGIONAL LYMPH NODE METASTASIS IS PREDICTED BY NORMAL PAPATION AND NORMAL TOMOGRAPHIC APPEARANCE |
| Saturday 11:15 am | Sharadha Sakthikumar | HARNESSING THE POWER OF AI FOR CANINE CANCER MUTATION CURATION: OPPORTUNITIES AND CHALLENGES |
| Saturday 11:30 am | Tim Fan | TOLERABILITY AND ACTIVITY OF ANCHORED CANINE INTERLEUKIN-12 (CANK-101) IN PET DOGS WITH ADVANCED MALIGNANT MELANOMA |
| Saturday 11:45 am | Pablo Delgado Bonet | SAFETY AND EFFICACY OF THE ONCOLYTIC ADENOVIRUS ICOCAV15 AS INTRATUMORAL THERAPY FOR CANINE GLIOMAS |